Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

MLA

Attard, Gerhardt, et al. “Abiraterone Acetate plus Prednisolone with or without Enzalutamide for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: Final Results from Two Randomised Phase 3 Trials of the STAMPEDE Platform Protocol.” The Lancet. Oncology, vol. 24, no. 5, May 2023, pp. 443–56. EBSCOhost, https://doi.org/10.1016/S1470-2045(23)00148-1.

APA

Attard, G., Murphy, L., Clarke, N. W., Sachdeva, A., Jones, C., Hoyle, A., Cross, W., Jones, R. J., Parker, C. C., Gillessen, S., Cook, A., Brawley, C., Gilson, C., Rush, H., Abdel-Aty, H., Amos, C. L., Murphy, C., Chowdhury, S., Malik, Z., … James, N. D. (2023). Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. The Lancet. Oncology, 24(5), 443–456. https://doi.org/10.1016/S1470-2045(23)00148-1

Chicago

Attard, Gerhardt, Laura Murphy, Noel W Clarke, Ashwin Sachdeva, Craig Jones, Alex Hoyle, William Cross, et al. 2023. “Abiraterone Acetate plus Prednisolone with or without Enzalutamide for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: Final Results from Two Randomised Phase 3 Trials of the STAMPEDE Platform Protocol.” The Lancet. Oncology 24 (5): 443–56. doi:10.1016/S1470-2045(23)00148-1.